No Data
Stocks that moved the day before yesterday Part 2 include Azjent, Dai Do Limited, Technisco, etc.
Stock name <Code> 5th day closing price ⇒ comparison with the previous day. Sakura Internet <3778> 4070 -170, especially without materials, trading is decreasing, and sell-off is dominant. New Japan Science <2395> 1354 -57, investment rating is downgraded by Jefferies Securities. Tohoku Electric Power <9506> 1382 -515, electric utility stocks are generally selling off on 5th day. Round One <4680> 801 -56, the trend of exhaustion is dominant after announcing existing stores in June. Japan Cash Machine <6418> 1161 -5.
Part 2 of the stocks that moved the day before, R Planner, Kasumigaseki Capital, Kawasaki Heavy Industries, etc.
Stock Name <Code> 4 day closing price ⇒ Previous day comparison. Kasumigaseki Capital <3498> 14860 -1350 Back selling is dominant after a sharp rise on the previous day. Kawasaki Heavy Industries <7012> 5978 -473 It is rumored that they are suspected of providing gold commodities to SDF members. ABC-Mart <2670> 2729.5 -145.5 There is a pre-sellout feeling without a surprise in the Q1 financial results. Ascle <2678> 2060 -100 Negative view of the slowdown in this year's earnings growth rate. ANYCOLOR <5>
Volume change rate ranking (9:00) ~ Delta-P, Recovery and others ranked in.
*In volume change rate ranking, by comparing the volume of the last 5 days and the volume on the day of distribution, you can understand the interest of market participants, such as market trends. *Volume Change Rate Top [As of July 4th 9:32 am] (Comparison of average volume of last 5 days) Stock Code Stock Name Volume 5-day average volume Volume change rate Price change rate<2247>iF500H none 16385 107185.08 182.7% 0.0035%<
DELTA-P has ranked in. The clinical phase III comparative trial of DFP-14323 has begun registration of cases.
DELTA-P＜4598＞ ranked in (as of 9:32AM). Although there were buying orders initially, the momentum slowed down. After the previous day's trading ended, they announced that the first case had been registered for the clinical phase III comparative trial (superiority verification trial) of DFP-14323 targeting patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations positive and stage III/IV. Initially, there was buying interest considering the announcement; however, buying interest could not be sustained and the stock showed heavy resistance. Top changes in volume % [July 4th 09:3
Strong, supported by low long-term US interest rates.
[Emerging Market Individual Stock Strategies] Today's emerging market is expected to develop strongly. In the U.S. stock market on the 3rd, the Dow Jones fell slightly by 23.85 dollars (-0.06%) to 39,308.00 dollars, marking a small fall for the third straight day. The market was supported by a weak labor-related indicator announced in the morning and a drop in long-term interest rates, amid a lack of momentum in the shortened trading session ahead of Independence Day. The Nasdaq index, pushed up by gains in Tesla and Nvidia, hit a record high and closed higher. Buy emerging markets today.
Delta-P, Tim's, and others
<3803> Established an imaging subsidiary <4598> Started clinical phase III comparative trial registration of Delta-PDFP-14323 <4889> Upside revision by Lina Science; expected operating loss of -257 million yen this fiscal year ← -275 million yen <usa> Launched phase I clinical trial at Eirion Therapeutics, Inc. <4891> Signed exclusive implementation license agreement with Hokkaido universities for a new treatment candidate for spinal cord injuries <universities> <7078> <No translation found>
No Data
